ACUR · As filed with the SEC
Acura Pharmaceuticals cash flow statement, by quarter
The statement as Acura Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | Q4 2021 3 months ended Dec 31, 2021 | Q3 2021 3 months ended Sep 30, 2021 | Q2 2021 3 months ended Jun 30, 2021 | Q1 2021 3 months ended Mar 31, 2021 |
|---|---|---|---|---|
| Cash Flows from Operating Activities: | ||||
| Net loss | — | — | — | (259,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | — | — | — | 11,000 |
| Non-cash stock-based compensation | — | — | — | 0 |
| Amortization of intangible asset | — | — | — | 7,000 |
| Impairment charge on intangible asset | — | — | — | 0 |
| Changes in assets and liabilities: | ||||
| Royalty receivable | — | — | — | 0 |
| Collaboration revenue receivable from related party | — | — | — | 93,000 |
| License fee receivable from related party | — | — | — | (400,000) |
| Prepaid expenses and other current assets | — | — | — | 55,000 |
| Accounts payable | — | — | — | 34,000 |
| Accrued expenses | — | — | — | 33,000 |
| Accrued interest on related party loans | — | — | — | 113,000 |
| Other current liabilities | — | — | — | 0 |
| Net cash used in operating activities | — | — | — | (313,000) |
| Cash Flows from Financing Activities: | ||||
| Proceeds from distribution of RSU awards | — | — | — | 3,000 |
| Statutory minimum payroll withholding taxes paid on the distribution of shares pursuant to RSU awards | — | — | — | (8,000) |
| Proceeds from loan under CARES Act | — | — | — | 266,000 |
| Net cash provided by financing activities | — | — | — | 261,000 |
| Net decrease in cash | — | — | — | (52,000) |
| Cash at beginning of period | 89,000 | 167,000 | 361,000 | 413,000 |
| Cash at end of end of period | 65,000 | 89,000 | 167,000 | 361,000 |
| Supplemental Disclosures of Cash Flow Information: | ||||
| Cash interest payments on loans | — | — | — | 0 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.